Glibenfage, 5 mg+500 mg 30 pcs

Name: Glibenfage, 5 mg+500 mg 30 pcs
SKU: 338548
Availability: OutOfStock

€1.00

Out of stock

(E-mail when Stock is available)

EAN: 4620017863205 SKU: 338548 Categories: Diabetes, Hypoglycemic drugs, Medicine

Description

Type 2 diabetes mellitus in adults:

when diet therapy, exercise, and prior monotherapy with metformin or sulfonylurea derivatives are ineffective;
to replace prior therapy with two drugs (metformin and sulfonylurea derivative) in patients with stable and adequate glycemic control.

Active ingredient

Glibenclamide, Metformin

Composition

Active ingredients:

Glibenclamide 5 mg + metformin hydrochloride 500 mg;

Auxiliary substances:

Core:

Hypromellose – 16.0 mg,

croscarmellose sodium – 18.0 mg,

Sodium stearyl fumarate – 7.0,

povidone K30 – 15.0 mg,

povidone (collidone F90) – 19.0 mg;

Composition of the film coating:

Hypromellose E15 – 7.0 mg, macrogol 6000 (polyethylene glycol 6000) – 0.9 mg, titanium dioxide – 2.0 mg, polysorbate 80 (Tween 80) – 0.1 mg.

How to take, the dosage

Oral.
The dose of the drug is determined by the doctor individually for each patient, depending on the concentration of glucose in the blood.

The initial dose is: 1 tablet of the drug Glibenfazh 2.5 mg + 500 mg or 5 mg + 500 mg once a day. To avoid hypoglycemia, the initial dose should not exceed the daily dose of glibenclamide (or the equivalent dose of another previously taken sulfonylurea drug) or metformin, if they were used as first-line therapy. It is recommended that the dose be increased by no more than 5 mg of glibenclamide and 500 mg of metformin daily every 2 or more weeks to achieve adequate blood glucose control.

Special Instructions

Treatment with the drug Glibenfazh is carried out only under the supervision of a doctor! When taking the drug, it is necessary to strictly follow the doctor’s recommendations on diet and self-monitoring of blood glucose concentration. Blood glucose concentration should be regularly monitored on an empty stomach and after meals.

Contraindications

Hypersensitivity to metformin, glibenclamide or other sulfonylurea derivatives or other excipients of the drug; type 1 diabetes mellitus; diabetic ketoacidosis, diabetic precoma, diabetic coma; renal insufficiency or impaired renal function (creatinine clearance < 60 ml/min); acute conditions that may lead to altered renal function: dehydration, severe infection, shock, intravascular administration of iodine-containing contrast agents (see "Special indications"); acute or chronic diseases that are accompanied by tissue hypoxia: cardiac or respiratory failure, recent myocardial infarction; liver failure; porphyria; pregnancy, breastfeeding; simultaneous use of miconazole; major surgery, injuries, extensive burns and other conditions that require insulin therapy; chronic alcoholism, acute alcohol intoxication; lactoacidosis (including history).including in anamnesis); compliance with a hypocaloric diet (less than 1000 kcal/d); children under 18 years of age.

Side effects

The following adverse reactions may occur during treatment with Glibenfage.
WHO Classification of the frequency of adverse reactions: very often – ≥1/10 prescriptions, often – from ≥1/100 to <1/10 prescriptions, infrequent – from ≥1/1000 to <1/100 prescriptions, rare – from ≥1/10000 to <1/1000 prescriptions, very rare – <1/10000 prescriptions.

Classification of adverse reactions according to organ and organ system involvement (Med-DRA Regulatory Medical Dictionary).

Overdose

In case of overdose, hypoglycemia may occur due to the presence of a sulfonylurea derivative in the drug (see “Cautions”).

Pregnancy use

The use of the combination of glibenclamide and metformin is contraindicated during pregnancy. The patient should be warned that during treatment with the drug Glibenfazh it is necessary to inform the doctor about the planned pregnancy and the onset of pregnancy. If pregnancy is planned, as well as if pregnancy occurs during the period of taking the drug, it should be cancelled and insulin therapy should be prescribed.

The combination of glibenclamide and metformin is contraindicated in breastfeeding because there are no data on its ability to penetrate into breast milk. If it is necessary to use the drug during breastfeeding, switch to insulin therapy or stop breastfeeding.

Similarities

Glibomet, Glucovance, Gluconorm, Gluconorm Plus, Metglyb Force

Additional information

Weight	0.032 kg
Shelf life	3 years.
Conditions of storage	In the original manufacturer's package at a temperature not exceeding 25 ° C. Store out of the reach of children.
Manufacturer	Pharmasintez-Tyumen, Russia
Medication form	pills
Brand	Pharmasintez-Tyumen